Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Shares of Zydus Life Sciences dropped 5.3% to Rs 1,232.40 on the BSE in early Monday trading. Brokerages are divided on the stock's outlook following its Q1 performance. Bank of America (BofA) maintains a neutral rating on Zydus Life, raising the target price to Rs 1,310 from Rs 1,235. Jefferies has issued a hold call on Zydus Life, raising the target to Rs 1,210 per share, noting a strong Q1 performance led by US operations with an EBITDA margin at an all-time high of 34%. The company's US segment grew 23% quarter-on-quarter to $373 million, driven by contributions from gRevlimid and Gmirabegron. Zydus Life has increased its FY25 revenue and margin guidance.
Jefferies On JB Chem Buy Call, Target Raised To Rs 2,230/Sh Q1 EBITDA Beat Our Estimates By 7% Domestic Business Including Acquired Ophthal Portfolio Grew 22% YoY (13% Organic Growth) Domestic Business Was Better Than Expected Mgmt Expects Domestic Business To Grow High-teens In…
#Jefferies On #Zydus Life Hold Call, Target Raised To Rs 1,210/Sh Co Delivered A Strong Q1 Led By US With EBITDA Margin At An All-time High Of 34% US Grew 23% QoQ To $373 m Driven By gRevlimid And Gmirabegron Contribution Co Increased Its FY25 Revenue And Margin Guidance There…
Jefferies On #ABB India Buy Call, Target Raised To Rs 9,230/Sh Q2CY24 EBITDA Was 17% Higher Than Expectations Q2CY24 EBITDA Beat Estimates As 630 bps YoY Gross Margins Expansion Offset 11% Revenue Miss Pricing Power And Revenue Mix Drove 360 bps Margin Expansion Co Saw `200 Cr…